The European Institute of Technology (EIT) has awarded the master programme International Master in Innovative Medicine (IMIM) an EIT Label. IMIM is a two-year Erasmus+ programme that is organized as a collaboration between the University of Groningen, Uppsala University in Sweden and Ruprecht-Karls-Universität Heidelberg in Germany. At the University of Groningen, the students follow some of the courses in the master programme Medical and Pharmaceutical Drug Innovation at the Graduate School of Medical Sciences.
The common thread throughout IMIM is the "From Bench to Bedside and Back" (BBB) concept, which fosters a full perspective on medical sciences, ranging from basic mechanisms of disease to drug design and clinical research.
According to Dr. Martijn Nawijn, Academic coordinator of IMIM, the EIT label is awarded only to very few MSc programs across Europe and this is the first Life Science MSc degree receiving this prestigious quality seal. “The EIT label recognizes the exceptional educational program of IMIM and specifically its capacity to help talented students develop the required skills and competences to address the 21st century challenges in an innovative and entrepreneurial fashion. Obtaining the EIT label is a recognition of the success of our efforts to create a translational and international MSc program together with our partners in Uppsala and Heidelberg. We are very happy and very proud indeed.”